Market Research Logo

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
    • The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
    • The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Graft Versus Host Disease (GVHD) Overview
    Therapeutics Development
    Pipeline Products for Graft Versus Host Disease (GVHD) - Overview
    Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis
    Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies
    Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes
    Graft Versus Host Disease (GVHD) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Graft Versus Host Disease (GVHD) - Products under Development by Companies
    Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes
    Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
    AbbVie Inc
    AbGenomics International, Inc.
    Actelion Ltd
    Alexion Pharmaceuticals Inc
    Amunix Operating Inc.
    Apceth GmbH & Co. KG
    arGEN-X BV
    Athersys, Inc.
    Bellicum Pharmaceuticals, Inc.
    Bio-Cancer Treatment International Limited
    Biogen Inc
    Bristol-Myers Squibb Company
    Cantex Pharmaceuticals, Inc.
    Capricor Therapeutics, Inc.
    Cell2B S.A.
    CellECT Bio, Inc.
    Cynata Therapeutics Limited
    Cytodyn Inc.
    Dompe Farmaceutici S.p.A.
    Dr. Falk Pharma GmbH
    Escape Therapeutics, Inc.
    F. Hoffmann-La Roche Ltd.
    Fate Therapeutics, Inc.
    Generon (Shanghai) Corporation Ltd.
    Gilead Sciences, Inc.
    GlaxoSmithKline Plc
    Idera Pharmaceuticals, Inc.
    ImmuNext, Inc.
    Immunomedics, Inc.
    Incyte Corporation
    Kadmon Corporation, LLC
    Kamada Ltd.
    Kiadis Pharma N.V.
    Kymab Limited
    Kyorin Pharmaceutical Co., Ltd.
    MacroGenics, Inc.
    Mallinckrodt Plc
    Medsenic
    Mesoblast Limited
    Millennium Pharmaceuticals Inc
    Neopharm Ltd.
    Nohla Therapeutics Inc.
    Novartis AG
    OncoImmune, Inc.
    OSE Immunotherapeutics
    Pharmicell Co., Ltd.
    REGiMMUNE Corporation
    Rigel Pharmaceuticals, Inc.
    Sarepta Therapeutics, Inc.
    Seattle Genetics, Inc.
    Seres Therapeutics, Inc.
    Sigmoid Pharma Limited
    Spherium Biomed S.L.
    Takeda Pharmaceutical Company Limited
    Targazyme, Inc.
    Therapix Biosciences Ltd.
    Tobira Therapeutics, Inc.
    Vault Pharma Inc.
    Xenikos B.V.
    ZIOPHARM Oncology, Inc.
    Graft Versus Host Disease (GVHD) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    abatacept - Drug Profile
    AbGn-168H - Drug Profile
    AGS-499 - Drug Profile
    aldesleukin - Drug Profile
    Alecmestencel-L - Drug Profile
    alpha-1 proteinase inhibitor (human) - Drug Profile
    ALXN-1007 - Drug Profile
    AMX-342 - Drug Profile
    anti-thymocyte globulin (rabbit) - Drug Profile
    Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile
    Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
    ARGX-115 - Drug Profile
    arsenic trioxide - Drug Profile
    ATIR-101 - Drug Profile
    BCT-200 - Drug Profile
    begelomab - Drug Profile
    Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile
    Biologics for Graft Versus Host Disease - Drug Profile
    bortezomib - Drug Profile
    BPX-501 - Drug Profile
    brentuximab vedotin - Drug Profile
    budesonide - Drug Profile
    cannabidiol - Drug Profile
    CAP-2003 - Drug Profile
    CD-24Fc - Drug Profile
    Cell Therapy for Graft Versus Host Disease - Drug Profile
    Cell Therapy for Graft-Versus Host Disease - Drug Profile
    Cellgram for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile
    cenicriviroc mesylate - Drug Profile
    CRCBT-080004 - Drug Profile
    CX-01 - Drug Profile
    cyclosporine CR + cyclosporine IR - Drug Profile
    CYP-001 - Drug Profile
    entospletinib - Drug Profile
    F-652 - Drug Profile
    FR-104 - Drug Profile
    Ha-7 - Drug Profile
    ibrutinib - Drug Profile
    ImmuneSafe - Drug Profile
    ImmuStem - Drug Profile
    IMO-8400 - Drug Profile
    IT-603 - Drug Profile
    IT-901 - Drug Profile
    itacitinib adipate - Drug Profile
    KD-025 - Drug Profile
    KRP-203 - Drug Profile
    KY-1005 - Drug Profile
    MAX-16H5 - Drug Profile
    MesoStem - Drug Profile
    methoxsalen - Drug Profile
    MGD-010 - Drug Profile
    milatuzumab - Drug Profile
    Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile
    natalizumab - Drug Profile
    nilotinib - Drug Profile
    obinutuzumab - Drug Profile
    OCU-300 - Drug Profile
    Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile
    panobinostat - Drug Profile
    PF-05285401 - Drug Profile
    ponesimod - Drug Profile
    Preimplantation Factor - Drug Profile
    PRO-140 - Drug Profile
    ProTmune - Drug Profile
    R-348 - Drug Profile
    Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile
    Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile
    Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile
    remestemcel-L - Drug Profile
    reparixin - Drug Profile
    RGI-2001 - Drug Profile
    RO-2959 - Drug Profile
    rovalpituzumab tesirine - Drug Profile
    ruxolitinib phosphate - Drug Profile
    S-Graft - Drug Profile
    SER-155 - Drug Profile
    Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile
    Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile
    Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
    Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile
    sonidegib phosphate - Drug Profile
    SP-12008 - Drug Profile
    SYGN-305 - Drug Profile
    Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile
    T-Guard - Drug Profile
    TZ-101 - Drug Profile
    vedolizumab - Drug Profile
    VPI-101 - Drug Profile
    ZL-1101 - Drug Profile
    Graft Versus Host Disease (GVHD) - Dormant Projects
    Graft Versus Host Disease (GVHD) - Discontinued Products
    Graft Versus Host Disease (GVHD) - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016
    Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Development by Companies, H2 2016 (Contd..4)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Investigation by Universities/Institutes, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc. , H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma N.V., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2016
    Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2016
    Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2016
    Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2016
    Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2016
    Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H2 2016
    Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016
    Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report